Skip to content
AnalystLens

Byrn, Inc. 8-K Report, Executive Changes (Jan 19, 2012)

Reports
Leadership Changes
Filing Date
Filed January 19, 2012
Period End
January 13, 2012
Security
BRRN
In the record · 2020–202610-K910-Q108-K6

BRRN filed 9 annual reports (10-K), 10 quarterly reports (10-Q) and 6 current reports (8-K) between 2020 and 2026.

  1. Change in control8-K · Feb ’21Feb ’21
  2. FY2024 annual report10-K · Apr ’25Apr ’25

01—Abstract

Summary

Summary of the 8-K filed January 19, 2012. Cited figures are marked; the original filing is the authoritative source.

This Form 8-K filing by Techs Loanstar, Inc. (TCLN) reports a significant leadership change within its wholly-owned subsidiary, Quture, Inc. Effective January 13, 2012, Dr. Richard D.

Fantozzi has been appointed as the Chief Executive Officer of Quture and Co-Chairman of its Board of Directors. Dr. Fantozzi brings a wealth of experience from his distinguished medical career, including leadership roles in medical boards and private practice, as well as experience in real estate investment through RDF Asset Group, Inc. His appointment is intended to leverage his prominence, expertise, and business leadership for Quture's growth.

In conjunction with this appointment, Mr. G. Landon Feazell has stepped down as CEO of Quture but will retain his roles as Co-Chairman of Quture's Board and as CEO, President, and Chairman of the Board of the parent company, Techs Loanstar, Inc. The compensation for Dr. Fantozzi includes 100,000,000 restricted shares of the company's common stock and a monthly salary of $6,500a.

02—Key points

Key Highlights

  1. Appointment of Dr. Richard D. Fantozzi as CEO and Co-Chairman of Quture, Inc. (a subsidiary of TCLN) effective January 13, 2012.
  2. Dr. Fantozzi has extensive background as a physician, medical regulator (former President of the Medical Board of California), and has experience with a real estate investment company.
  3. Mr. G. Landon Feazell transitions from CEO of Quture to Chief of Innovations of Quture.
  4. Mr. Feazell retains his executive and board positions with the parent company, Techs Loanstar, Inc. (CEO, President, Chairman).
  5. Dr. Fantozzi's compensation package includes 100,000,000 restricted shares of TCLN common stock.
  6. Dr. Fantozzi will receive a monthly salary of $6,500.
  7. The company cites Dr. Fantozzi's prominence, expertise, and business leadership as reasons for his selection.

03—Questions

Frequently Asked Questions

  1. What is the primary reason for this Form 8-K filing?

    The primary reason for this filing is to announce significant leadership changes at Quture, Inc., a wholly-owned subsidiary of Techs Loanstar, Inc. Specifically, it details the appointment of a new CEO for Quture and a role change for the existing CEO.

  2. Who is Dr. Richard D. Fantozzi and what are his qualifications?

    Dr. Richard D. Fantozzi is a physician (M.D., F.A.C.S.) with a distinguished career. His qualifications include serving as President of the Medical Board of California, former Director of Head/Neck Surgery at Scripps Clinic, and President of RDF Asset Group, Inc., a real estate investment company. He was selected for his prominence, expertise, and experience as a physician, regulator, and business leader.

  3. What are the terms of Dr. Fantozzi's compensation?

    Dr. Fantozzi will be compensated with 100,000,000 restricted shares of Techs Loanstar, Inc.'s common stock and a monthly salary of $6,500.

  4. What is Mr. G. Landon Feazell's new role?

    Mr. G. Landon Feazell has transitioned from his role as CEO of Quture, Inc. to Chief of Innovations of Quture, Inc. He remains as CEO, President, and Chairman of the Board of Directors for the parent company, Techs Loanstar, Inc., and also continues as Co-Chairman of Quture's Board of Directors.

04—Continue

← View all 8-K filings